Protocol Ledger

NCT06672549 · Phase III · RECRUITING

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Interventional Phase III clinical trial protocol NCT06672549 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-18 Enrollment: 125 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06672549
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)125 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06672549
Protocol FieldVerified Registry Value
NCT IdentifierNCT06672549
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment125 participants (ESTIMATED)
Registered Start Date2024-11-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI